Using MRI to Improve Detection of Tumor Recurrence After Brain Treatment
Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases
This study is testing if a new type of MRI can help doctors tell the difference between damage from radiation and tumor recurrence in adults with brain metastases who have had previous treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 37 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT04246879 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate whether an additional MRI sequence can enhance the differentiation between radiation-induced damage and tumor recurrence in patients with brain metastases who have undergone stereotactic radiosurgery (SRS). Participants will include adults with metastatic solid tumors who have experienced radiographic progression at previously treated SRS sites. The study will involve administering MRI scans to assess the effectiveness of this new imaging approach. The goal is to improve diagnostic accuracy and treatment planning for these patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with metastatic solid tumors and at least one brain metastasis previously treated with SRS.
Not a fit: Patients with small cell lung cancer or those deemed poor surgical candidates may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection of tumor recurrence, allowing for timely and appropriate treatment interventions.
How similar studies have performed: While the approach of using advanced MRI techniques is promising, the specific application in this context is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients, age ≥18 * Metastatic malignancy with at least 1 brain metastasis previously treated with SRS * Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation * Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma. * Radiographic progression on post-SRS imaging at previously treated SRS site(s) * Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team * Patients must sign study-specific informed consent prior to study entry Exclusion Criteria: * Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team * Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy) * Small cell lung cancer (SCLC) or lymphoma histology
Where this trial is running
Durham, North Carolina
- Duke University Health System — Durham, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Scott Floyd, M.D. Ph.D. — Duke Health
- Study coordinator: Eileen Duffy, RN OCN
- Email: eileen.duffy@duke.edu
- Phone: 919 668 3726
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.